Core Viewpoint - Chengdu Shengnuo Biotechnology Co., Ltd. announced its participation in the national organized procurement of pharmaceuticals, with several products expected to be selected for the new round of procurement, which is a significant step for the company in expanding its market presence and enhancing competitiveness in the peptide pharmaceutical market [1][2]. Group 1: Selected Products - The company’s subsidiary, Chengdu Shengnuo Pharmaceutical Co., Ltd., participated in the national organized procurement for the first to eighth batches, with products such as Acetate Octreotide Injection and Acetate Atosiban Injection expected to be selected [1]. - The selected products include Acetate Octreotide Injection (seventh batch), Acetate Atosiban Injection (eighth batch), Somatostatin Injection (eighth batch), Thymosin Alpha 1 Injection, and Eptifibatide Injection [1]. Group 2: Impact on the Company - The selected products are expected to enhance the company's sales revenue significantly in 2024 and the first nine months of 2025, with the procurement cycle running until the end of 2028 [2]. - The procurement will prioritize the use of selected drugs in medical institutions, ensuring the completion of the agreed procurement volume, which is expected to positively impact the company's operational development [2]. - The selection also reflects the stability and reliability of the company's drug quality, which is crucial for its competitive position in the peptide pharmaceutical market [2].

Core Viewpoint - Shengnuo Biopharmaceutical (688117.SH) announced that its wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., participated in the national organized procurement for the first to eighth batches of drugs, marking the first nationwide unified continuation procurement for chemical drugs [1] Group 1 - The continuation procurement is based on the results of the "Proposed Selected Results for Continuation Procurement of Expired National Organized Procurement Drugs" [1] - The company's products, including Acetate Octreotide Injection (selected in the seventh batch), Acetate Atosiban Injection (selected in the eighth batch), and Somatostatin Injection (selected in the eighth batch), are among those proposed for selection in this new round of procurement [1] - New products selected for this round include Thymosin Alpha 1 Injection and Exenatide Injection, which are also part of the proposed selections [1]

Core Viewpoint - The company, Shengnuo Biopharmaceutical (688117.SH), announced its participation in the national centralized procurement process for pharmaceuticals, marking the first nationwide unified continuation procurement for chemical drugs [1] Group 1: Procurement Participation - The company's wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., is involved in the first to eighth batches of the national centralized procurement [1] - This continuation procurement is significant as it represents the first nationwide unified continuation for chemical drugs organized by the state [1] Group 2: Selected Products - The company’s products, including Acetate Octreotide Injection (selected in the seventh batch), Acetate Atosiban Injection (selected in the eighth batch), and Somatostatin Injection (selected in the eighth batch), are among those proposed for selection in this new round of procurement [1] - Additionally, the company has new products proposed for selection, including Thymosin Alpha 1 Injection and Exenatide Injection [1]

证券代码：688117 证券简称：圣诺生物 公告编号：2026-002 | | | 占公 司 2024 | | 占公司 2025 年前三 | | --- | --- | --- | --- | --- | | 拟中选产品 | 2024 年销售收 | 年度 | 2025年1-9月 | 季度营 | | | 入（元） | 营业 | 销售收入（元） | 业收入 | | | | 收入 | | 比例 | | | | 比例 | | （%） | | | | （%） | | | | 醋酸奥曲肽注射剂 1ml:0.1mg | 58,503,254.76 | 12.83 | 38,224,482.51 | 7.35 | | 醋酸阿托西班注射剂 0.9ml:6.75mg | 1,920,360.16 | 0.42 | 1,314,098.27 | 0.25 | | 醋酸阿托西班注射剂 | 102,391,236.06 | 22.45 | 77,990,534.41 | 14.99 | | 5ml:37.5mg | | | | | | 生长抑素注射剂 3mg | 20,666,126.39 | 4.53 | 20,569,313.05 ...

Core Viewpoint - The company, Shengnuo Biopharmaceutical (688117.SH), has participated in the national centralized procurement process for the first to eighth batches of drugs, marking a significant step in expanding its market presence and enhancing competitiveness in the peptide pharmaceutical market [1] Group 1: Procurement Participation - The company’s wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., has engaged in the new round of centralized procurement organized by the state, which is the first nationwide unified continuation of centralized procurement for chemical drugs [1] - The company’s products, including Acetate Octreotide Injection (selected in the seventh batch), Acetate Atosiban Injection (selected in the eighth batch), and Somatostatin Injection (selected in the eighth batch), are among those proposed for selection in this new round of procurement [1] Group 2: Market Impact - The centralized procurement will prioritize the use of selected drugs by medical institutions, ensuring the completion of the agreed procurement volume [1] - The selection in this procurement round reflects the stability and reliability of the company’s drug quality, which is expected to further expand the sales scale of the selected products and increase market share [1] - The implementation of the procurement contract is anticipated to positively impact the company's operational development and strengthen its competitiveness in the peptide pharmaceutical market [1]

Core Viewpoint - The announcement indicates that the company’s wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., is participating in the national centralized procurement of medicines, which includes multiple products selected in recent rounds of procurement [1] Group 1: Procurement Participation - The company’s products, including Acetate Octreotide Injection (selected in the seventh batch), Acetate Atosiban Injection, and Somatostatin Injection (both selected in the eighth batch), are part of the national procurement initiative [1] - The company is also proposing new products for selection in the upcoming procurement round, including Thymosin Alpha 1 Injection and Exenatide Injection [1]

Core Viewpoint - The company, Shengnuo Biopharmaceutical (688117.SH), has participated in the national centralized procurement for the first to eighth batches of drugs, marking the first nationwide unified continuation of centralized procurement for chemical drugs [1] Group 1: Procurement Participation - The company’s wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., is involved in the new round of continuation procurement organized by the state [1] - The continuation procurement includes the company’s products such as Acetate Octreotide Injection (selected in the seventh batch), Acetate Atosiban Injection (selected in the eighth batch), and Somatostatin Injection (selected in the eighth batch) [1] Group 2: Market Impact - The selected products will be prioritized for use by medical institutions during the procurement period, ensuring the completion of the agreed procurement volume [1] - The selection in this continuation procurement reflects the stability and reliability of the company’s drug quality, which is expected to expand the sales scale of the selected products and increase market share [1] - This development is anticipated to strengthen the company’s competitiveness in the peptide pharmaceutical market and positively impact its operational growth [1]

Group 1 - The core viewpoint of the news is that Shengnuo Bio has shown significant financial growth, with a notable increase in revenue and net profit for the first nine months of 2025 [2] - As of January 29, Shengnuo Bio's stock price decreased by 0.46%, with a trading volume of 89.92 million yuan and a net financing purchase of 3.20 million yuan [1] - The company's financing balance is 464 million yuan, accounting for 7.53% of its market capitalization, which is below the 50th percentile level over the past year, indicating a low financing position [1] Group 2 - Shengnuo Bio's revenue for the period from January to September 2025 reached 520 million yuan, representing a year-on-year growth of 53.96% [2] - The net profit attributable to the parent company for the same period was 127 million yuan, showing a substantial increase of 123.03% year-on-year [2] - The company has distributed a total of 87.14 million yuan in dividends since its A-share listing, with 63.14 million yuan distributed over the past three years [3]

Group 1 - The company formerly known as 财讯传媒集团有限公司 has officially changed its name to BFB Health Limited [1] - The Chinese stock abbreviation has been updated from "财讯传媒" to "BFB HEALTH" [1] - BFB HEALTH has signed a strategic cooperation agreement with A-share listed company 圣诺生物 to collaborate in the biomedicine sector [1]

A股 Market Updates - On January 15, multiple A-share companies released their performance forecasts for 2025, with many expecting significant profit increases. SAIC Motor Corporation anticipates a net profit growth of up to 558%, while companies like Shengnuo Biological and Zhenghai Magnetic Materials expect increases exceeding 200% [2] - Jiamei Packaging announced that its stock has triggered redemption clauses due to its closing price being above 130% of the conversion price for 15 out of the last 30 trading days [2] - ST Chengchang and Zhizhi New Materials announced their resumption of trading after completing investigations into recent abnormal stock price fluctuations [2] - ST Aowei reported that its stock closed at 0.99 CNY per share, warning that if it remains below 1 CNY for 20 consecutive trading days, it may face delisting from the Shenzhen Stock Exchange [2] Logistics and E-commerce - SF Holding and Jitu Express announced a strategic mutual shareholding agreement, involving an investment transaction amounting to nearly 8.3 billion HKD [3] - Ctrip is under investigation by the State Administration for Market Regulation, leading to a significant drop in its stock price, with a 6.49% decline on the day of the announcement and a further 20% drop the following day, resulting in a market value loss exceeding 100 billion CNY [3] Financial Data - In 2025, the total number of new A-share accounts reached 27.44 million, a 10% increase year-on-year, marking a three-year high, with total A-share investors exceeding 250 million [4] - The People's Bank of China reported that by the end of 2025, the social financing scale reached 442.12 trillion CNY, growing by 8.3% year-on-year, while the RMB loan balance was 271.91 trillion CNY, up 6.4% [5] - The China Securities Regulatory Commission approved an adjustment to the margin ratio for financing, increasing the minimum margin requirement from 80% to 100%, effective January 19, 2026 [5] Gold Reserves - As of the end of November 2025, non-U.S. countries' official gold reserves exceeded 900 million troy ounces, valued at approximately 3.82 trillion USD [6] Infrastructure and Technology - The State Grid Corporation announced that its fixed asset investment is expected to reach 4 trillion CNY during the 14th Five-Year Plan, a 40% increase from the previous plan [7] - Alibaba's Qianwen App has integrated with various Alibaba ecosystem services, launching over 400 AI functionalities to enhance user experience in daily tasks [7] - Shanghai's new action plan aims to implement L4 autonomous driving technology in various scenarios by 2027, targeting over 6 million passenger trips and 800,000 TEU in freight transport [7] Housing Policy - A joint announcement from the Ministry of Finance, State Taxation Administration, and Ministry of Housing and Urban-Rural Development extended personal income tax policies supporting housing purchases from January 1, 2026, to December 31, 2027 [8] Trade Performance - China's total foreign trade in 2025 reached 45.47 trillion CNY, a 3.8% increase, setting a historical record and maintaining its position as the world's largest goods trading nation [8]